Palmitoylation of AMPA Receptors is lnvolved in the lnhibition of Hippocampal Long-term Potentiation by Aluminum Exposure in Rats＊

SONG Jing, XIA Xin Yu, GAO Ting, YUAN Chun Man, LU Xiao Ting,WANG Lin Ping, and ZHANG Hui Fang

Aluminum (Al) is the most abundant metal in the Earth’s crust and is widely used in everyday life and industry.Al is neurotoxic to mammals.Epidemiological studies have confirmed the positive relationship between an increased environmental Al concentration and cognitive impairment[1].Hippocampal long-term potentiation (LTP) has been widely used as a neuronal model of synaptic plasticity in experiments designed to elucidate the synaptic mechanisms involved in the loss of learning and memory[2].The alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)-type glutamate receptor (AMPAR), a major glutamategated ion channel in the mammalian central nervous system, plays important roles in synaptic transmission, synaptic plasticity such as LTP, and learning and memory cognitive function of the brain.LTP typically results from an increased concentration of AMPARs at the postsynaptic membrane surface[3].

A reversible post-translational modification by the addition of a long-chain fatty acid to a cysteine residue of the AMPAR, called S-palmitoylation, is critical for the modulation of AMPAR function, which dynamically regulates protein stability, transport,and activity and is the key element of LTP[4].This process is a distinctive, reversible lipid modification and potentially regulates the function of AMPARviacycles of palmitoylation and depalmitoylation, which are catalyzed by protein palmitoyltransferases and thioesterases, respectively[5].However, the role of AMPA palmitoylation in the impairment of LTP induced by Al exposure is still poorly understood.

Here, we aimed to investigate the possible link between AMPA palmitoylation and the impairment of LTP induced by Alin vivoand to clarify the underlying mechanisms.First, to explore the involvement of palmitoylation in Al-induced LTP suppression, we administered different doses of Al to rats and determined the palmitoylation levels of glutamate receptor 1 (GluR1) and GluR2 after LTP measurement.Second, the expression of palmitoyltransferase (zDHHC3) and palmitoyl protein thioesterase-1 (PPT1) in the hippocampi of rats were tested at the same time to confirm the changes in palmitoylation and depalmitoylation.

In accordance with the methods of Al(mal)3preparation described in our previous publication[5],AlCl3·6H2O (Sigma-Aldrich, St.Louis, MO, USA) was dissolved in distilled water to concentrations of 20,40, and 80 mmol/L.Maltolate was dissolved in phosphate-buffered saline to concentrations of 60,120, and 240 mmol/L.Al(mal)3solution is the mixed solution of AlCl3·6H2O and maltol solutions.Al(mal)3was freshly prepared for each experiment by mixing the solutions in equal volumes, adjusting the pH to 7.4 with NaOH, and filtering the solutions through 0.22 μm syringe filters.The total Al concentration after filtration were 10, 20, and 40 mmol/L.

The experiments were performed on 2-monthold male Sprague-Dawley rats (SPF grade, the Laboratory Animal Center, Shanxi Medical University, Taiyuan, China) kept under constant temperature and humidity conditions with free access to food and water.The rats (weight 180-200 g)were randomly divided into four groups (n= 6 per group), namely, control, low-dose, medium-dose,and a high-dose group, in the subchronic Al treatment procedure and received saline (control group) or Al(mal)3(10, 20, and 40 μmol/(kg·d) bwviaan intraperitoneal injection every two days for 12 weeks.After electrophysiological measurements were performed, the rats were decapitated, and the hippocampi were rapidly removed for biochemical analyses and stored at -80 °C until use.The present study was approved by the Ethics Committee for Animal Studies of Shanxi Medical University.All efforts were made to minimize the number of animals used and their suffering.SPSS 22.0 software(SPSS Co.Ltd., Chicago, IL, USA) was used to analyze all results.Experimental data are expressed as the means ± standard deviation.Differences among groups were analyzed using one-way analysis of variance, followed by the least significance difference test for multiple comparisons when F was significant.Correlation analysis was used to analyze the correlation between the amplitude of the standardized field excitatory postsynaptic potential(fEPSP) and the palmitoylation of GluR1 and GluR2 in the hippocampus and the correlation between GluR1 and GluR2 palmitoylation and zDHHC3 and PPT1 protein expression.P-values ＜ 0.05 were considered significant.

Except for the 40 μmol/kg Al(mal)3group, the remaining rats developed normally and were lively and active over the study period.The rats in the 40 μmol/kg Al(mal)3group showed poor response and had dull fur.No spontaneous animal mortality was observed during the course of the study.As shown in Supplementary Table S1 (available in www.besjournal.com), Al exposure resulted in reduced net increase of body weight (F= 25.522,P＜ 0.05).Decreases were observed in brain indices compared with the control group at the end of Al exposure, but the difference was not statistically significant (F=3.521,P= 0.085).

The LTP in the hippocampal CA1 region was measured by electrophysiological measurementsin vivo.The surgical procedure and electrophysiological recordings were performed in accordance with the methods described in our previous publication[5].With the increase in Al(mal)3concentrations, the average value of the fEPSP amplitude gradually decreased after high frequency stimulation (HFS)(Figure 1A).The fEPSP amplitudes at four time points were selected for statistical analysis (Figure 1B).No significant difference was recorded in the basic fEPSP amplitude in the control and Al-exposed rats.The fEPSP amplitudes of the control group (n= 5) were(2.20 ± 0.17), (1.95 ± 0.09), and (1.82 ± 0.02) at 1, 30, and 60 min after HFS, respectively.The fEPSP amplitudes of the 10 μmol/kg Al(mal)3group (n= 5) were (1.99 ±0.07) at 1 min, (1.70 ± 0.09) at 30 min, and (1.57 ±0.10) at 60 min after HFS, presenting a slight but significant decrease compared with the control group (P＜ 0.05).These values dropped to (1.76 ±0.05), (1.41 ± 0.12), and (1.35 ± 0.11) in the 20 μmol/kg Al(mal)3group (n= 5,P＜ 0.05) and further decreased to (1.50 ± 0.10), (1.22 ± 0.11), and(1.05 ± 0.04) in the 40 μmol/kg Al(mal)3group (n= 5,P＜ 0.05).The difference in LTP was evident between the Al(mal)3exposure groups and control group, and further suppression became notable with the increase Al(mal)3concentrations.These findings were consistent with those of a previous report[5].The findings indicate that the animal model was established successfully and was suitable to study the mechanism of LTP induced by Al in detail.

The palmitoylation levels of AMPAR subunits(GluR1 and GluR2) in the hippocampus were detected by immunoprecipitation and acyl-biotin exchange assay, which was performed in accordance with the methods described in previous publication[6].Two dosages (20 and 40 μmol/kg of Al)of Al(mal)3induced significant changes in the palmitoylation levels of GluR1 (F= 3.3348,P＜ 0.05)and GluR2 (F= 23.07,P＜ 0.05) compared with those in the control group (Figure 2).Significantly, the level of palmitoylation of GluR2 in 40 μmol/kg Al(mal)3rats decreased compared with that in control group and 10 and 20 μmol/kg Al(mal)3groups (P＜ 0.05).As shown in Supplementary Figures S1A and S1B(available in www.besjournal.com), the correlation analysis between the standardized fEPSP amplitudes and the palmitoylation levels of GluR1 and GluR2 in the hippocampus showed that the standardized fEPSP amplitude at 60 min after HFS in the rat hippocampus positively correlated with the palmitoylation levels of GluR1 (r= 0.660,P＜ 0.05)and GluR2 (r= 0.895,P＜ 0.05).The results showed that with the increase in Al concentrations, the palmitoylation levels of GluR1 and GluR2 gradually decreased.We found a positive correlation between LTP and the palmitoylation of GluR1 and GluR2.Therefore, we hypothesized that LTP damage may be related to the decrease in the palmitoylation level of AMPAR.However, the mechanisms of this effect are unclear.

The protein and gene concentrations of zDHHC3 and PPT1 in the hippocampus were measured by Western blotting and reverse transcription polymerase chain reaction,respectively.We observed that with the increase in the Al concentration, the expression of zDHHC3 gradually decreased, whereas the expression of PPT1 gradually increased.The results regarding the gene and protein are consistent.As shown in Figure 3A, the increase in Al(mal)3concentration decreased the relative intensities of zDHHC3 (F=21.34,P＜ 0.05) in a dose-dependent manner compared with that in the control group.The relative intensity of zDHHC3 in the 40 mmol/kg Al(mal)3group was significantly lower than those in the control and 10 mmol/kg Al(mal)3groups.With the increase in Al(mal)3concentrations, the gene levels of zDHHC3 gradually decreased (F=17.00,P＜ 0.05) compared with that in the control group (Figure 3B).In the 40 μmol/kg Al(mal)3group, the gene level of zDHHC3 substantially decreased compared with those in the control and 10 μmol/kg Al(mal)3groups (P＜ 0.05).Increasing the Al(mal)3concentration increased the protein expression of PPT1 compared with that in the control group (F= 5.10,P＜ 0.05) (Figure 3C).As shown in Figure 3D, Al-induced dose-dependent increases of PPT1 gene expression also occurred(F= 75.60,P＜ 0.05), andPPT1gene expression in the 20 and 40 μmol/kg Al(mal)3groups remarkably increased compared with that in the 10 μmol/kg Al(mal)3group (P＜ 0.05).Thus, Al may influence the expression of zDHHC3 and PPT1 in the rat hippocampus and further influence the palmitoylation of AMPAR.Correlation analysis(Supplementary Figure S2C-S2F available in www.besjournal.com) showed that the expression level of zDHHC3 was positively correlated with the palmitoylation levels of GluR1 and GluR2, and that the expression level of PPT1 was negatively correlated with the palmitoylation of GluR1 and GluR2, which supports this view.

The mechanism responsible for the effects of Al exposure on zDHHC3 and PPT1 is not fully elucidated.One possible aspect of this mechanism regarding zDHHC3 is the high affinity of Al for the metal binding sites in enzymes due to its small size and near maximal charge; this affinity causes Al to disrupt critical enzymatic reactions.The zDHHC3 catalytic motif is located within a cysteine-rich, zinc finger-like domain which relies on Zn2+normal function[7].Al3+can compete with and substitute for essential metals in enzyme reactions because these reactions normally rely on metals having a rapid reversible dissociation; meanwhile, Al has very slow release rate from the ligands to which it binds.Al3+dissociates from biological ligands 107more slowly than Zn2+[8].Al3+replaces Zn2+in several Zn2+-containing enzyme proteins[9].We speculate that Al3+may inhibit the activity of zDHHC3 by competitively replacing Zn2+in the zinc finger structure, thereby affecting the enzymatic reaction of palmitoylation modification.In addition, PPT1 is palmitoylatedin vivoand is a substrate for two palmitoylating enzymes, zDHHC3 and DHHC7[10].Therefore, we hypothesized that Al may enhance the activity of PPT1 by affecting zDHHC3.

In summary, we provide strong evidence that the decrease in AMPAR palmitoylation is involved in the impairment of hippocampal LTP.Additionally,zDHHC3 and PPT1 may be the Al targets that influence the AMPAR cycles of palmitoylation and depalmitoylation, respectively.This conclusion raises the possibility that the palmitoylation of AMPARs may be a new molecular event contributing to preventing the influence of Al on learning and memory to a certain degree and may lead to the exploration of valid targets to treat diseases correlated to Al.

AcknowledgmentsWe sincerely thank our colleagues for their help and work on the research.Conflicts of interestThe authors declare no conflicts of interest.

#Correspondence should be addressed to SONG Jing,Tel: 86-351-4135240, E-mail: sj4933749@126.com

Biographical note of the first author: SONG Jing,female, born in 1979, Associate Professor, PhD, majoring in occupational health.

Received: April 14, 2020;

Accepted: July 22, 2020